Immuron (IMRN) Other Non-Current Liabilities (2017 - 2025)
Immuron (IMRN) posted quarterly Other Non-Current Liabilities of $718.55 for Q3 2025, down 45.95% year-on-year from $1329.4 in Q3 2024, and down 98.58% on a QoQ basis from $50745.8 in Q2 2025.
Immuron (IMRN) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Immuron (IMRN) has reported Other Non-Current Liabilities for 8 consecutive years, with $718.55 the latest figure, recorded in Q3 2025.
- Quarterly Other Non-Current Liabilities fell 45.95% year-over-year to $718.55 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $718.55 (down 45.95% YoY) and the FY2025 annual result came in at $718.55, down 45.95% from the prior year.
- Other Non-Current Liabilities eased to $718.55 in Q3 2025 per IMRN's latest filing, from $50745.8 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for IMRN reached as high as $150325.0 in Q2 2023 and fell as low as $718.55 in Q3 2025.
- A 5-year average of $64913.2 and a median of $65279.9 in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 8998.41% — and 2023, when it sank 99.26%.
- Year by year, Other Non-Current Liabilities stood at $1361.6 in 2021, then soared by 8998.41% to $123879.6 in 2022, then plunged by 99.26% to $920.04 in 2023, then surged by 6995.32% to $65279.9 in 2024, then plunged by 98.9% to $718.55 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $718.55, $50745.8, and $65279.9 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 718.55 |
| Jun 30, 2025 | 50,745.77 |
| Dec 31, 2024 | 65,279.88 |
| Sep 9, 2024 | 1,329.41 |
| Jun 30, 2024 | 93,886.21 |
| Dec 31, 2023 | 920.04 |
| Sep 28, 2023 | 106,163.22 |
| Aug 30, 2023 | 1,503.25 |
| Jun 30, 2023 | 150,325.00 |
| Dec 31, 2022 | 123,879.58 |
| Aug 31, 2022 | 123,879.58 |
| Jun 30, 2022 | 123,879.58 |
| Dec 31, 2021 | 1,361.55 |
| Sep 1, 2020 | 18,929.00 |
| Jun 30, 2020 | 13,368.13 |
| Dec 31, 2019 | 189.29 |
| Dec 31, 2017 | -828,980.65 |